<div id="readability-page-1"><div> By Adriano Marchese <pre></pre> Iovance Biotherapeutics shares rose after the company received positive data from a clinical trial of its cancer treatment. Shares traded 11% higher ahead of the morning bell at $2.18. The biotechnology company, which specializes in cell therapies for cancer, on Monday said that about 26% of patients responded to the lifileucel monotherapy treatment in Phase 2 testing, including two who saw their cancer disappear. The San Carlos, Calif., company said the disease-control rate, or the proportion of patients who had their disease stabilize or improve, was at about 72%. Iovance said it plans to present more data in 2026 and hopes to progress toward a biologics license application with the Food and Drug Administration next year as well. It aims for a potential launch in the second half of 2027, it said. <pre></pre> Write to Adriano Marchese at adriano.marchese@wsj.com <pre></pre> (END) Dow Jones Newswires November 03, 2025 09:40 ET (14:40 GMT)Copyright (c) 2025 Dow Jones &amp; Company, Inc.</div></div>

Iovance生物治疗

Iovance 生物治疗的股票在盘前交易中上涨了 11%，至 2.18 美元，此前其癌症治疗药物 lifileucel 的第二阶段试验结果积极。约有 26% 的患者对该治疗产生了反应，疾病控制率为 72%。该公司计划在 2026 年发布更多数据，并计划明年向 FDA 提交生物制品许可申请，目标是在 2027 年下半年推出

Iovance 生物治疗公司的股票在盘前交易中因其癌症药物的积极试验数据而上涨